We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

This study is currently recruiting participants.
Verified October 2017 by Poseida Therapeutics, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT03288493
First Posted: September 20, 2017
Last Update Posted: October 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Poseida Therapeutics, Inc.
September 13, 2017
September 20, 2017
October 6, 2017
September 20, 2017
December 31, 2018   (Final data collection date for primary outcome measure)
Maximum tolerated dose of P-BCMA-101 based on dose limiting toxicities [ Time Frame: Baseline through Day 28 ]
Rate of dose limiting toxicities
Safety and maximum tolerated dose of P-BCMA-101 based on dose limiting toxicities [ Time Frame: Baseline through Day 28 ]
Rate of dose limiting toxicities
Complete list of historical versions of study NCT03288493 on ClinicalTrials.gov Archive Site
  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Baseline through Month 24 ]
    Incidence and severity of treatment-emergent adverse events
  • Anti-myeloma effect of P-BCMA-101(Response Rate) [ Time Frame: Baseline through Month 24 ]
    Percentage of patients with complete response (CR), very good partial response (VGPR), or partial response (PR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma.
  • Anti-myeloma effect of P-BCMA-101(Duration of Response) [ Time Frame: Baseline through Month 24 ]
    Time from complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma.
  • Anti-myeloma effect of P-BCMA-101(Progression Free Survival) [ Time Frame: Baseline through Month 24 ]
    Time from P-BCMA-101 treatment to progressive disease according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma.or death
  • Anti-myeloma effect of P-BCMA-101(Overall Survival) [ Time Frame: Baseline through Month 24 ]
    Duration of survival from time of treatment with P-BCMA-101
  • Pharmacokinetics of P-BCMA-101 [ Time Frame: Baseline through Month 24 ]
    Concentration of P-BCMA-101 cells in blood and bone marrow over time
  • Biomarkers for P-BCMA-101 [ Time Frame: Baseline through Month 24 ]
    Levels of BCMA in blood and bone marrow cells
Same as current
Not Provided
Not Provided
 
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects With Relapsed and/or Refractory Multiple Myeloma (MM)
This is a Phase 1, open-label, multi-center study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed and/or refractory MM.
The study will follow a 3 + 3 design of dose-escalating cohorts. After a patient enrolls, leukapheresis will be performed to obtain peripheral blood mononuclear cells which will be sent to a manufacturing site to produce P-BCMA-101 CAR-T cells. The cells will then be returned to the investigational site and, after a standard chemotherapy based conditioning regimen, will be administered to the patient. Treated patients will undergo serial measurements of safety, tolerability and response.
Interventional
Phase 1
Intervention Model: Single Group Assignment
Intervention Model Description:
3 + 3 design of dose-escalating cohorts
Masking: None (Open Label)
Primary Purpose: Treatment
Multiple Myeloma
Biological: P-BCMA-101 CAR-T cells
P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a "safety switch" gene to allow the cells to be eliminated if desired.
Experimental: P-BCMA-101 CAR-T cells
single dose, intravenous infusion, CAR-T cells
Intervention: Biological: P-BCMA-101 CAR-T cells
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
June 30, 2021
December 31, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males or females, ≥18 years of age
  • Must have a confirmed diagnosis of active MM
  • Must have measurable MM
  • Must have relapsed and/or refractory MM, having received treatment with proteasome inhibitor and IMiD
  • Must have adequate hepatic, renal, cardiac and hematopoietic function

Exclusion Criteria:

  • Is pregnant or lactating
  • Has inadequate venous access and/or contraindications to leukapheresis
  • Has active hemolytic anemia, plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, amyloidosis, significant autoimmune, CNS or other malignant disease
  • Has an active systemic infection
  • Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol
  • Has receiving immunosuppressive or other contraindicated therapies within the excluded time frame from entry
  • Has CNS metastases or symptomatic CNS involvement
  • Has a history of having undergone allogeneic stem cell transplantation, or any other allogeneic or xenogeneic transplant
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Michelle Resler 1-858-779-3100 mresler@poseida.com
Contact: Casey Salem 1-910-399-1028 casey.salem@chiltern.com
United States
 
 
NCT03288493
P-BCMA-101-001
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc.
Not Provided
Study Director: Matthew A Spear, M.D. Sponsor Chief Medical Officer
Poseida Therapeutics, Inc.
October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP